Results 81 to 90 of about 21,135 (199)

Week 48 resistance analyses of the once-daily, single-tablet regimen darunavir/cobicistat/emtricitabine/tenofovir alafenamide (D/C/F/TAF) in adults living with HIV-1 from the Phase III Randomized AMBER and EMERALD Trials [PDF]

, 2019
Darunavir/cobicistat/emtricitabine/tenofovir alafenamide (D/C/F/TAF) 800/150/200/10 mg is being investigated in two Phase III trials, AMBER (NCT02431247; treatment-naive adults) and EMERALD (NCT02269917; treatment-experienced, virologically suppressed ...
Ajana, F, Antela, A, Antinori, A, Arasteh, K, Arribas, JR, Baugh, Bryan, Belonosova, E, Benson, P, Berenguer, J, Bhatti, L, Bickel, M, Bogner, J, Bredeek, F, Brown, Kimberley, Brunetta, J, Casado, J, Castelli, F, Chernova, O, Chirianni, A, Clarke, A, Conway, B, Cotte, L, Crofoot, G, Cunningham, D, De Los Santos, I, De Luca, A, De Meyer, Sandra, De Wit, S, DeJesus, E, deVente, J, Di Biagio, A, Dushkina, N, Eron, J, Esser, S, Estrada, V, Faetkenheuer, G, Felizarta, F, Florence, E, Franco, R, Galindo, MJ, Gallant, J, Galli, M, Garcia Del Toro, M, Garlicki, A, Gasiorowski, J, Gatell, JM, Gazzard, BG, Ghys, Anne, Girard, P-M, Gorgolas, M, Gutierrez, F, Gutierrez, MDM, Hagins, D, Halota, W, Henry, K, Horban, A, Jayaweera, D, Jessen, H, Jezorwski, John, Johnson, MA, Katlama, C, Kern, W, Klein, M, Kulagin, V, Lathouwers, Erkki, Lazzarin, A, Lucasti, C, Maggiolo, F, Martorell, C, Maserati, R, McDonald, C, McGowan, J, Mills, A, Mohsine, El Ghazi, Molina, J-M, Morales-Ramirez, J, Moutschen, M, Murphy, D, Mussini, C, Negredo, E, Opsomer, Magda, Orkin, C, Parczewski, M, Piekarska, A, Pineda, JA, Podzamczer, D, Poizot-Martin, I, Portilla Sogorb, J, Prelutsky, D, Rachlis, A, Raffi, F, Ramgopal, M, Rashbaum, B, Reeves, I, Rey, D, Reynes, J, Rivero, A, Rockstroh, J, Ruane, P, Rubio, R, Ryamova, E, Shafran, S, Shuldyakov, A, Sizova, N, Slim, J, Spinner, C, Stellbrink, H-J, Stoehr, A, Teicher, E, Tsybakova, O, Van Landuyt, Erika, Van Wijngaerden, E, Vandekerckhove, L, Vandercam, B, Vekerckhove, L, Vercam, B, Viciana, P, Voronin, E, Walmsley, S, Waters, L, Wilkin, A, Wong, Eric Y, Yakovlev, A, Yazdanpanah, Y   +123 more
core   +3 more sources

The Next Frontier: Micro/Nanorobots Operating Inside the Living Body

SmartBot, Volume 2, Issue 1, March 2026.
Micro/nanorobots, with their tiny size and controllable motion capabilities, can perform complex and precise tasks in micro‐spaces, thus showing broad application prospects in the biomedical field. This review systematically summarizes the core advantages of micro/nanorobots in real‐time in vivo imaging, targeted drug delivery, and active barrier ...
Ningbo Yu, Jie Yang, Zicheng Ni, Yuepeng Cai, Beatriz Jurado‐Sánchez, Renfeng Dong   +5 more
wiley   +1 more source

Interactions of tenofovir, lamivudine, abacavir and didanosine in primary human cells [PDF]

, 2011
Certain triple nucleoside/tide reverse transcriptase inhibitor (NRTI) regimens containing tenofovir (TDF) have been associated with rapid early treatment failure. The mechanism is unknown, but may be at the level of drug transport.
Balimane, Bousquet, Brenner, Chandler, Cihlar, de Souza, Gallant, Gibbs, Gibbs, Giri, Hawkins, Imaoka, Janneh, Janneh, Janneh, Janneh, Kewn, Kewn, Khanlou, Maitland, Mallants, Minderman, Minuesa, Omar Janneh, Pan, Podzamczer, Robbins, Saye Khoo, Shaik, Shiraki, Storch, Tong, Turriziani, van Gelder, Wang, Wang, Waters, Weiss   +37 more
core   +2 more sources

Tenofovir Alafenamide Fumarate Reduces Virological Replication in HBeAg‐Negative Patients With Normal Alanine Aminotransferase: A 48‐Week Randomised Controlled Trial

Journal of Viral Hepatitis, Volume 33, Issue 3, March 2026.
ABSTRACT The optimal strategy for chronic hepatitis B virus (HBV) infected patients with negative hepatitis B e‐antigen (HBeAg) and normal alanine aminotransferase (ALT) remains uncertain. This study aimed to evaluate the safety and efficacy of tenofovir alafenamide fumarate (TAF) treatment in this patient population.
Qiumin Luo, Wenxiong Xu, Yeqiong Zhang, Xiangyong Li, Jing Lai, Jianguo Li, Xingrong Zheng, Hong Deng, Lubiao Chen, Xiang Zhu, Chan Xie, Liang Peng   +11 more
wiley   +1 more source

Antiviral Efficacy and Safety of Tenofovir Alafenamide Compared to Tenofovir Disoproxil Fumarate in the Treatment of Chronic Hepatitis B

Central Asian Journal of Medical Sciences, 2020
Objectives: To provide compare of the efficacy and safety tenofovir alafenamide (TAF) to tenofovir disoproxil fumarate (TDF) in patients with HBeAg-negative and HBeAg-positive chronic hepatitis B.
Tuvshinbayar Narangerel, Amaraa Ravdan, Gegeebadrakh Baljinnyam, Burmaajav Badrakh, Baatarkhuu Oidov   +4 more
doaj   +1 more source

Role of pharmacists in HIV prophylaxis: a scoping review of pharmacists’ services, interventions and outcomes

Journal of the International AIDS Society, Volume 29, Issue 2, February 2026.
Abstract Introduction HIV remains a major global public health challenge, with nearly 1.3 million new HIV acquisitions annually. Despite the effectiveness of pre‐exposure (PrEP) and post‐exposure prophylaxis (PEP), barriers to access, initiation and adherence persist.
Gustavo Magno Baldin Tiguman, Amanda Veiga Barbosa das Dores, Patricia Melo Aguiar   +2 more
wiley   +1 more source

Switching from tenofovir disoproxil fumarate to tenofovir alafenamide fumarate in a cohort of patients with HBV infection: A retrospective study

Journal of Clinical Virology Plus
Background: Tenofovir disoproxil fumarate (TDF) as first-line therapy for chronic HBV infection is related to nephrotoxicity. Tenofovir alafenamide fumarate (TAF) has been approved with a similar virological and serological response, but lower toxicity ...
Giacomo Stroffolini, Valentina Dodaro, Amedeo De Nicolò, Jessica Cusato, Giovanni Di Perri, Antonio D'Avolio, Lucio Boglione   +6 more
doaj   +1 more source

A Review and Clinical Understanding of Tenofovir: Tenofovir Disoproxil Fumarate versus Tenofovir Alafenamide

Journal of the International Association of Providers of AIDS Care, 2020
HIV is a serious chronic medical condition. Significant improvements in antiretroviral therapy have led to a transformation in its management. No curative treatment is available for HIV, and lifelong therapy is required with a combination of agents to ...
Chanie Wassner PharmD, BCCCP, BCIDP, Nicole Bradley PharmD, BCPS, BCIDP, Yuman Lee PharmD, BCIDP, AAHIVP   +2 more
doaj   +1 more source

Role of antiviral therapy in the natural history of hepatitis B virus-related chronic liver disease [PDF]

, 2015
Hepatitis B virus (HBV) infection is a dynamic state of interactions among HBV, hepatocytes, and the host immune system. Natural history studies of chronic hepatitis B (CHB) infection have shown an association between active viral replication and adverse
Farinati, Fabio, Gottardo, G, Rodr\uedguez Castro, K, Russo, FRANCESCO PAOLO, Scribano, L, Vanin, V   +5 more
core   +1 more source

Changes in proteinuria and albuminuria with initiation of antiretroviral therapy: data from a randomized trial comparing tenofovir disoproxil fumarate/emtricitabine versus abacavir/lamivudine [PDF]

, 2014
BACKGROUND: Antiretroviral therapy (ART) is associated with improved kidney function; however, the nucleotide reverse transcriptase inhibitor (NRTI) tenofovir disoproxil fumarate (TDF) has been associated with decreased kidney function and proteinuria ...
AIDS Clinical Trials Group Study A5224s Team, Daar, Eric S., Gupta, Samir K., Ha, Belinda, Kitch, Douglas, McComsey, Grace A., Melbourne, Kathleen, Sax, Paul E., Tierney, Camlin, Wyatt, Christina M.   +9 more
core   +2 more sources